Cardiotonic Steroids as a Potential Novel Approach for Immunomodulation in Inflammatory Bowel Disease

TL;DR

This paper reviews how cardiotonic steroids, known for heart effects, might help treat inflammatory bowel disease by modulating the immune system.

Contribution

The paper introduces cardiotonic steroids as a novel immunomodulatory approach for inflammatory bowel disease.

Findings

Cardiotonic steroids show potential to modulate immune responses in inflammatory bowel disease.

Current IBD treatments have limited efficacy, highlighting the need for new therapeutic options.

These steroids may target dysbiosis and inflammatory pathways linked to IBD pathogenesis.

Abstract

Inflammatory bowel disease (IBD) is a chronic condition that significantly impairs the quality of life of millions of individuals. The pathogenesis of IBD is closely linked to dysbiosis of microbiota and the activation of various inflammatory pathways, which are characterized by elevated levels of activated immune cells, such as neutrophils and lymphocytes. While several therapeutic options, including corticosteroids and biologic agents, are available for the treatment of IBD, their efficacy remains limited. Consequently, the development of novel therapies is essential. In this context, cardiotonic steroids, a class of drugs traditionally known for their effects on the cardiovascular system, have gained attention due to their potential immunomodulatory properties. Thus, this review aims to explore the emerging therapeutic potential of cardiotonic steroids in the treatment of IBD.

Figures